events

CMTA-STAR Alliance Partner NMD Pharma Shares New SYNAPSE-CMT Trial Data

NMD Pharma shared new data from its Phase 2a SYNAPSE-CMT clinical trial evaluating the investigational drug ignaseclant during a late-breaking presentation at the 2026 MDA Clinical & Scientific Conference.

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A – (CANADA ONLY)

About this Study The purpose of this study is to characterize the safety, tolerability, and...

CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update

New Phase 2a CMT trial results are in. NMD Pharma shares details.

Under the Microscope: Reproductive Choices in CMT

CMTA-STAR Under the Microscope graphic titled “Reproductive Choices in CMT,” presenting a patient-friendly overview of family planning options for people living with Charcot-Marie-Tooth disease.

For people living with Charcot-Marie-Tooth disease, decisions about family planning can raise complex and deeply personal questions. This Under the Microscope installment explores various reproductive options and family planning resources.

Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?

Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.

What Can Long-Read Sequencing Reveal About CMT?

What happened when CMTA-supported scientists at University College London applied long-read sequencing to CMT cases that had no genetic confirmation for years?